Globus Medical, Inc. $GMED is Paradice Investment Management LLC’s Largest Position

Paradice Investment Management LLC raised its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 20.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 663,038 shares of the medical device company’s stock after purchasing an additional 114,433 shares during the period. Globus Medical accounts for about 8.5% of Paradice Investment Management LLC’s portfolio, making the stock its biggest position. Paradice Investment Management LLC owned about 0.49% of Globus Medical worth $37,972,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Boston Trust Walden Corp bought a new position in shares of Globus Medical during the 3rd quarter valued at approximately $67,891,000. Norges Bank purchased a new position in Globus Medical during the second quarter worth $68,038,000. Marshall Wace LLP increased its position in Globus Medical by 89.7% during the second quarter. Marshall Wace LLP now owns 1,580,476 shares of the medical device company’s stock valued at $93,280,000 after acquiring an additional 747,330 shares during the last quarter. Burgundy Asset Management Ltd. lifted its holdings in shares of Globus Medical by 24.3% in the 2nd quarter. Burgundy Asset Management Ltd. now owns 3,481,438 shares of the medical device company’s stock worth $205,474,000 after acquiring an additional 679,691 shares during the last quarter. Finally, Sculptor Capital LP lifted its holdings in shares of Globus Medical by 31.9% in the 2nd quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock worth $162,936,000 after acquiring an additional 667,850 shares during the last quarter. 95.16% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

GMED has been the topic of several analyst reports. Royal Bank Of Canada upped their price target on shares of Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 6th. Stifel Nicolaus started coverage on Globus Medical in a research note on Tuesday, October 28th. They set a “hold” rating and a $64.00 price target for the company. Wells Fargo & Company boosted their price objective on Globus Medical from $66.00 to $79.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Canaccord Genuity Group upped their price objective on Globus Medical from $90.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Eight equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $93.11.

Insider Transactions at Globus Medical

In related news, Director Ann D. Rhoads sold 2,000 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $85.00, for a total value of $170,000.00. Following the completion of the sale, the director directly owned 15,384 shares of the company’s stock, valued at $1,307,640. This represents a 11.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Kelly Huller sold 7,500 shares of the stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $90.00, for a total transaction of $675,000.00. The SEC filing for this sale provides additional information. Insiders sold a total of 86,042 shares of company stock valued at $7,419,030 over the last three months. 18.54% of the stock is currently owned by corporate insiders.

Globus Medical Stock Performance

Shares of NYSE GMED opened at $88.36 on Tuesday. The firm has a market capitalization of $11.83 billion, a price-to-earnings ratio of 28.50, a PEG ratio of 1.63 and a beta of 1.06. The stock has a 50 day moving average price of $80.72 and a 200 day moving average price of $65.98. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $94.93.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, November 6th. The medical device company reported $1.18 EPS for the quarter, topping the consensus estimate of $0.79 by $0.39. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.The company had revenue of $769.05 million for the quarter, compared to the consensus estimate of $734.58 million. During the same period last year, the business posted $0.83 EPS. Globus Medical’s quarterly revenue was up 22.9% on a year-over-year basis. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. Analysts forecast that Globus Medical, Inc. will post 3.44 earnings per share for the current year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.